Rebecca S. Sippel, MD, associate professor of surgery, University of Wisconsin, Madison, Wisconsin, explains that multiple studies have shown that the incidence and diagnosis of thyroid cancer is on the rise; however, the cause of this increase is largely unknown.
The major risk factors that call for added screening for thyroid cancer are radiation exposure and a positive family history. Unfortunately, the genetics of familial thyroid cancer are complicated and not well understood, Sippel believes. However, it is clear that every person with a first-degree relative that had thyroid cancer should be screened more aggressively.
The FDA’s Molecular and Clinical Genetics advisory committee has unanimously supported the safety, efficacy, and positive risk-benefit profile of the noninvasive stool-based DNA test Cologuard in a 10-0 vote.
The blood-based colorectal cancer (CRC) screening test Epi proColon passed the scrutiny of the FDA’s Molecular and Clinical Genetics advisory panel in a close 5-4 vote with 1 abstention in support of the claim that the test’s benefits outweigh its risks
Screening for prostate-specific antigen (PSA) significantly cuts the death rate from prostate cancer, so America’s medical community should continue to offer the test to appropriate men, but at the same time should work harder to avoid the screen’s potential pitfalls.